|
Ìåäèêî-áèîëîãè÷åñêèé
èíôîðìàöèîííûé ïîðòàë
|
 |
äëÿ ñïåöèàëèñòîâ |
|
|
|
Vol. 12, Art. 82 (pp. 990-1013) | 2011
Oxygen carrying hemoglobin-based blood substitutes
Selivanov E.A.1, Pshenkina N.N.2, Murzina E.V.2, Sofronov G.A.2,
Khanevich M.D.2, Sarychev V.A.3 1- Russian Research Institute for Hematology and Transfusiology of Health Ministry of Russian Federation, 2 Sovetskaya, 16, Saint Petersburg, 191024 2- Military Medical Academy named after S.M. Kirov, Academic Lebedev str., 6, Saint Petersburg, 194044 3- Gelenpol, Ltd., Marx pr., 14, Obninsk, Kaluga region, 249035
Brief summary
Substantial efforts to develop a blood substitutes on the base of modified hemoglobin have been made since the end of last century. The review reflects main achievements and complications on the way of development of hemoglobin-based oxygen carriers. Key words hemoglobin, oxygen-carrying blood substitutes, preclinical and clinical trials, adverse effects. (The article in PDF format. For preview need Adobe Acrobat Reader)  Open article in new window
Reference list 1. Vorobev S.I. Perftoryglerodnie emylsii I i II pokoleniya // Him.-farm. jyrn. – 2009. – T. 43. – ¹ 4. S. 30-40. 2. Golybev A.M., Beloyarcev F.F., Vasilev A.E., Pokrovskii U.E. Reakcii biologicheskih sistem pri zameshenii krovi emylsiyami ftoryglerodov. M.: TEIS, 1993. 3. Dyakonov A.N., Byrdanov A.P., Korik V.E., Konovalov S.V. Primenenie gelenpola pri operaciyah na tolstoi kishke // Primenenie infyzionnih antigipoksantov i iskysstvennih perenoschikov kisloroda v hiryrgii: Sb. naych. tr. / SPb. 1999. S. 16-18. 4. Ivanickii G.R. Biofizika na poroge novogo tisyacheletiya: perftoryglerodnie sredi i gazotransportnie krovezameniteli // Biofizika – 2001. – T.46. – ¹ 1. – S. 5-33. 5. Korik V.E. Primenenie krovezamenitelya-perenoschika kisloroda na osnove modificirovannogo gemoglobina pri lechenii bolnih s tyajeloi krovopoterei // Avtoref. diss… kand. med. nayk. – SPb., 2000. 6. Kyznecova N.P., Gydkin L.R., Mishaeva R.N. Sposob polycheniya poligemoglobina s povishennoi kislorodtransportnoi effektivnostu / Patent RU 2132687, 1999. 7. Kyznecova N.P., Gydkin L.R., Selivanov E.A. i dr. Krovezamenitel- perenoschik kisloroda, sostav dlya ego polycheniya i sposob polycheniya polimernogo modificirovannogo gemoglobina / Patent RU2162707, 2001. 8. Samsonov G.V. i dr. Solevoi rastvor polimernogo gemoglobina / Patent SU183354A3, 1992. 9. Selivanov E.A., Bistrova I.M., Hanevich M.D., Parashin M.E. Eksperimentalnoe i klinicheskoe izychenie krovezamenitelya-perenoschika kisloroda na osnove modificirovannogo gemoglobina // Fiziologicheski aktivnie veshestva na osnove perftoryglerodov v voennoi medicine: Sb. mater. naych. konf. / SPb. 1997. – S. 95-96. 10. Selivanov E.A., Sofronov G.A., Hanevich M.D. i dr. Effektivnost primeneniya perftorana v hiryrgicheskoi praktike // Transfyziologiya. – 2008. – ¹ 2. – S. 78-88. 11. Selivanov E.A., Sofronov G.A., Hanevich M.D., Skryabin O.N. Vozmojnosti primeneniya modificirovannogo gemoglobina v hiryrgii // Transfyziologiya. – 2008. – T.9. – ¹ 2. – S. 68-77. 12. Sklifas A.N., Shehtman D.G., Obrazcov V.V. i dr. Mehanizmi raspredeleniya i vivedeniya perftoryglerodov pri mnogokratnih vvedeniyah // Biofizika. – 1998. – T.43. – ¹1. – S. 171-176. 13. Sofronov G.A., Selivanov E.A., Hanevich M.D. Perenoschiki kisloroda: sostoyanie problemi i perspektivi razvitiya // Primenenie infyzionnih antigipoksantov i iskysstvennih perenoschikov kisloroda v hiryrgii: Sb. naych. tr. / SPb. 1999. – S. 75-85. 14. Syhorykov V.P., Ragimov A.A., Pyshkin S.U. i dr. Perftoran – perftoryglerodnii krovezamenitel s gazotransportnoi fynkciei // Posobie dlya vrachei. – 2-e izd., pererab. i dop. / Moskva.: B.i., 2008. 15. Filatov F.P. Virysnaya bezopasnost perelivaniya krovi // Priroda. 2005. ¹ 3. URL: http://vivovoco.rsl.ru/VV/JOURNAL/NATURE/03_05/VIRUS.HTM 16. Hanevich M.D., Sofronov G.A., Selivanov E.A., Korik V.E. Primenenie iskysstvennogo perenoschika kisloroda na osnove modificirovannogo gemoglobina y bolnih s gastrodyodenalnimi krovotecheniyami // Vestn. hiryrgii im. I.I. Grekova. 2000. – T. 159. – ¹ 6. – S. 51-54. 17. Shevchenko U.L., Shabalin V.N., Zarivchackii M.F., Selivanov E.A. Rykovodstvo po obshei i klinicheskoi transfyziologii // SPb.: «Foliant», 2003. 18. Yarochkin V.S., Kochemasov V.V. Gemodiluciya. Nastoyashee i bydyshee // M.: B.i., 1997. 19. Alayash A.I. Redox and Radical Reactions of Hemoglobin Solutions: Toxicities and Protective Strategies // In: Blood Substitutes. Ed. by R. Winslow / San Diego: Academic Press, 2006. – P. 197-205. 20. Amberson W.R. Blood substitutes // Biol. Rev. 1937. Vol. 12. P. 48-85. 21. Benesch R.E., Benesch R., Renthal R.D., Maeda N. Affinity labeling of the polyphosphate binding site of hemoglobin // Biochemistry. – 1972. – Vol. 11. – ¹ 19. – R. 3576- 3582. 22. Björkholm M., Fagrell B., Przybelski R. et al. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human Hb modified with maleimide-activated polyethylene glycol // Haematologica. – 2005. – Vol. 90. – ¹ 4. – P. 505-515. 23. Blood substitutes. Ed. by R. Winslow / San Diego: Academic Press. – 2006. 24. Carmichael F.J., Ali A.C., Campbell J.A. et al. A phase I study of oxidized raffinose cross-linked human hemoglobin // Crit. Care Med. – 2000. – Vol. 28. – ¹ 7. – P. 2283- 2292. 25. Carson J.L., Noveck H., Berlin J.A., Gould S.A. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion // Transfusion. – 2002. – Vol. 42. – ¹ 7. – R. 812-818. 26. Chang T.M. A nanobiotechnologic therapeutic that transport oxygen and remove oxygen radicals: for stroke, hemorrhagic shock and related conditions // In: Artificial cells: biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation and cell/stem cell therapy. Ed. by T.M. Chang / Singapore: World Science Publisher, 2007. P. 62-92. 27. Chang T.M. Nanobiotechnology for Hemoglobin-based blood substitutes // Crit. Care Clin. – 2009. – Vol. 25. – ¹ 2. – P. 373-382. 28. Cheng D.C. Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink) in cardiac surgery // Can. J. Anaesth. – 2001. – Vol. 48. – ¹ 4 (Suppl.) – S. 41-48. 29. Cohn C.S., Cushing M.M. Oxygen therapeutics: perfluorocarbons and blood substitute safety // Crit. Care Clin. – 2009. – Vol. 25. – ¹ 2. – P. 399-414. 30. D’Agnillo F., Chang T.M. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties // Nat. Biotechnol. – 1998. – Vol.16. – ¹ 7. – R. 667-671. 31. Drobin D., Kjellstrom B.T., Malm E. et al. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4) // J. Appl. Physiol. – 2004. – Vol. 96. – ¹ 5. – P. 1843-1853. 32. Epstein J.S., Holmberg J.A. Progress in monitoring blood safety // Transfusion. – 2010. – Vol. 50. – ¹ 7. – P. 1408-1412. 33. Gould S.A., Moore E.E., Hoyt D.B. et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery // J. Am. Coll. Surg. – 1998. – Vol. 187. – ¹ 2. – R. 113-120. 34. Gould S.A., Moore E.E., Hoyt D.B. et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable // J. Am. Coll. Surg. – 2002. – Vol. 195. – ¹ 4. – R. 445-452. 35. Gould S.A., Moore E.E., Moore F.A. et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery // J. Trauma. – 1997. – Vol. 43. – ¹ 2. – R. 325-331. 36. Greenburg A.G., Kim H.W. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery // J. Am. Coll. Surg. – 2004. – Vol. 198. – ¹ 3. – R. 373- 385. 37. Henkel-Honke T., Oleck M. Artificial oxygen carriers: a current review // AANA J. – 2007. – Vol. 75. – ¹ 3. – P. 205-211. 38. Hill S.E., Gottschalk L.I., Grichnik K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery // J. Cardiothorac. Vasc. Anesth. – 2002. – Vol. 16. – ¹ 6. – R. 695-702. 39. Hoffman S.J., Looker D.L., Roehrich J.M. et al. Expression of fully functional tetrameric human hemoglobin in Escherichia coli // Proc. Natl. Acad. Sci. USA. – 1990. – Vol. 87. – ¹ 21. – R. 8521-8525. 40. Izumi Y., Sakai H., Kose T. et al. Evaluation of the capabilities of a hemoglobin vesicle as an artificial oxygen carrier in a rat exchange transfusion model // ASAIO J. – 1997. – Vol. 43. – ¹ 4. – R. 289-297. 41. Jahr J.S., Varma N. PolyHeme. Northfield Laboratories // IDrugs. – 2004. – Vol. 7. – ¹ 5. – R. 478-482. 42. Jahr J.S., Weeks, D.L., Desai, P. et al. Does OxyVita, a new-generation hemoglobin based oxygen carrier, or Oxyglobin acutely interfere with coagulation compared with normal saline or 6% hetastarch? // J. Cardiothorac. Vas. Anesth. – 2008. – Vol. 22. – ¹ 1. – R. 34-38. 43. Jia Y., Alayash A.I. Effects of cross-linking and zero-link polymerization on oxygen transport and redox chemistry of bovine hemoglobin // Biochim. Biophys. Acta. – 2009. – Vol. 1794. – ¹ 8. – P. 1234-1242. 44. Kasper S.M., Walter M., Grüne F. et al. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery // Anesth. Analg. – 1996. – Vol. 83. – ¹ 5. – R. 921-927. 45. Kerger H., Tsai A.G., Saltzman D.J. et al. Fluid resuscitation with O2 vs. non-O2 carriers after 2 h of hemorrhagic shock in conscious hamsters // Am. J. Physiol. – 1997. – Vol. 272. – ¹ 1 (Pt. 2) – H525-537. 46. Kerner T., Ahlers O., Veit S. et al. DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study // Intensive Care Med. – 2003. – Vol. 29. – ¹ 3. – R. 378-385. 47. Kim H.W., Greenburg A.G. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status // Artif. Organs. – 2004. – Vol. 28. – ¹ 9. – P. 813-828. 48. Kim H.W ., Greenburg A.G. Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others // Artif. Cells Blood Substit. Immobil. Biotechnol. – 2006. – Vol. 34. – ¹ 6. – R. 537-550. 49. LaMuraglia G.M., O'Hara P.J., Baker W.H. et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution // J. Vasc. Surg. – 2000. – Vol. 31. – ¹ 2. – R. 299-308. 50. Lamy M.L., Daily E.K., Brichant J.F. et al. Randomized trial of diaspirin crosslinked hemoglobin solution as an alternative to blood transfusion after cardiac surgery // Anesthesiology. – 2000. – Vol. 92. – ¹ 3. – R. 646-656. 51. Levy J.H., Goodnough L.T., Greilich P.E. et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial // J. Thorac. Cardiovasc. Surg. – 2002. – Vol. 124. – ¹ 1. – R. 35-42. 52. Loeb A.L., McIntosh L.J., Raj N.R., Longnecker D.E. Resuscitation after hemorrhage using recombinant human hemoglobin (rHb1.1) in rats: effects on nitric oxide and prostanoid systems // Crit. Care Med. – 1998. – Vol. 26. – ¹ 6. – R. 1071-1080. 53. Looker D., Abbott-Brown D., Cozart P. et al. A human recombinant haemoglobin designed for use as a blood substitute // Nature. – 1992. – Vol. 356. – ¹ 6366. – R. 258-260. 54. Lowe K.C. Genomics and blood substitutes for 21st century Europe ("EuroBloodSubstitutes") // Artif. Cells Blood Substit. Immobil. Biotechnol. – 2006. – Vol. 34. – ¹ 6. – P. 589-599. 55. Lowenstein C.J., Dinerman J.L., Snyder S.H. Nitric oxide: a physiologic messenger // Ann. Intern. Med. – 1994. – Vol. 120. – ¹ 3. – R. 227-237. 56. Malhotra A.K., Kelly M.E., Miller P.R. et al. Resuscitation with a novel hemoglobin-based oxygen carrier in a Swine model of uncontrolled perioperative hemorrhage // J. Trauma. – 2003. – Vol. 54. – ¹ 5. – R. 915-924. 57. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology // Pharmacol. Rev. – 1991. – Vol.43. – ¹ 2. – R. 109-142. 58. Moore E.E., Moore F.A., Fabian T.C. et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial // J. Am. Coll. Surg. – 2009. – Vol. 208. – ¹ 1. – P. 1-13. 59. Moskowitz D.M ., McCullough J.N., Shander A. et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective? // Ann. Thorac. Surg. – 2010. – Vol. 90. – ¹ 2. – R. 451-458. 60. Murphy G.J., Reeves B.C., Rogers C.A. et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery // Circulation. – 2007. – Vol. 116. – ¹ 22. – P. 2544–2552. 61. Nakaki T. Physiological and clinical significance of nitric oxide // Keio J. Med. – 1994. – Vol. 43. – ¹ 1. – R. 15-26. 62. Natanson C., Kern S.J., Lurie P. et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis // JAMA. – 2008. – Vol. 299. – ¹ 19. – P. 2304-2312. 63. Ness P.M., Cushing M.M. Oxygen therapeutics. Pursuit of an alternative to the donor red blood cell // Arch. Pathol. Lab. Med. – 2007. – Vol. 131. – ¹ 5. – P. 734-741. 64. Ning J., Wong L.T., Christoff B. et al. Haemodynamic response following a 10% topload infusion of HemolinkTM in conscious, anaesthetized and treated spontaneously hypertensive rats // Transfus. Med. – 2000. – Vol. 10. – ¹ 1. – R. 13-22. 65. Olofsson C., Ahl T., Johansson T. et al. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery // Anesthesiology. – 2006. – Vol. 105. – ¹ 6. – P. 1153-1163. 66. Pearce L.B., Gawryl M.S., Rentko V.T. et al. HBOC-201 (Hemoglobin Glutamer- 250 (Bovine), Hemopure®): Clinical studies // In: Blood substitutes. Ed. by R. Winslow / San Diego: Academic press, 2006. – P. 437-450. 67. Pirie E., Green J. A framework to support safe blood transfusion practice // Nurs. Stand. – 2010. – Vol. 24. – ¹ 48. – P. 35-40. 68. Powanda D.D., Chang T.M. Cross-linked polyhemoglobin-superdioxide dismutase-catalase supplies oxygen without causing blood-brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion // Art. Cells Blood Subsstit. Immobil. Biotechnol. – 2002. – Vol. 30. – ¹ 1. – P. 25-42. 69. Riess J.G. Oxygen carriers (“blood substitutes”) - raison d’etre, chemistry and some physiology // Chem. Rev. – 2001. – Vol.101. – ¹ 9. – P. 2797-2920. 70. Saezler R.K., Arfors K.E., Tuma R.F. et al. Polynitroxylated hemoglobin-based oxygen carrier: inhibition of free radical induced microcirculatory dysfunction // Free Radic. Biol. Med. – 1999. – Vol. 27. – ¹ 1-2. – P. 1-6. 71. Sakai H., Horinouchi H., Yamamoto M. et al. Acute 40 percent exchangetransfusion with hemoglobin-vesicles (HbV) suspended in recombinant human serum albumin solution: Degradation of HbV and erythropoiesis in a rat spleen for 2 weeks // Transfusion. – 2006. – Vol. 46. – ¹ 3. – R. 339-347. 72. Sakai H., Masada Y., Horinouchi H. et al. Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats // Crit. Care Med. – 2004. – Vol. 32. – ¹ 2. – R. 539-545. 73. Sakai H., Sou K., Horinouchi H. et al. Hemoglobin-vesicles as artificial oxygen carriers: present situation and future visions // J. Intern. Med. – 2008. – Vol. 263. – ¹ 1. – P. 4- 15. 74. Sakai H., Sou K., Horinouchi H. et al. Review of hemoglobin-vesicles as artificial oxygen carriers // Artif. Organs. – 2009. – Vol. 33. – ¹ 2. – R. 139-145. 75. Sakai H., Sou K., Tsuchida E. Hemoglobin-vesicles as an artificial oxygen carrier // Methods Enzymol. – 2009. – Vol. 465. – P. 363-384. 76. Sakai H., Takeoka S., Park S.I. et al. Surface modification of hemoglobin vesicles with poly(ethylene glycol) and effects on aggregation, viscosity, and blood flow during 90% exchange transfusion in anesthetized rats // Bioconjug. Chem. – 1997. – Vol.8. – ¹1. – R. 23-30. 77. Sakai H., Tomiyama K., Sou K. et al. Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state// Bioconjug. Chem. – 2000. – Vol. 11. – ¹ 3. – R. 425-432. 78. Savitsky J.P., Doczi J., Black J., Arnold J.D. Clinical safety trial of stroma-free hemoglobin // Clin. Pharmacol. Ther. – 1978. – Vol. 23. – ¹ 1. – R. 73-80. 79. Schubert A., Przybelski R.J., Eidt J.F. et al. Diaspirin-crosslinked hemoglobin reduces blood transfusion in noncardiac surgery: a multicenter, randomized, controlled, doubleblinded trial // Anesth. Analg. – 2003. – Vol. 97. – ¹ 2. – R. 323-332. 80. Selivanov E.A., Kochetygov N.L., Bistrova I.M. et al. Study of polymerized hemoglobin in experiment // Artif. Cells Blood Substit. Immobil. Biotechnol. – 1994. – Vol. 22. – ¹ 5. – P. 156. 81. Siegel J.H., Fabian M., Smith J.A., Costantino D. Use of recombinant hemoglobin solution in reversing lethal hemorrhagic hypovolemic oxygen debt shock // J. Trauma. – 1997. – Vol. 42. – ¹ 2. – R. 199-212. 82. Simoni J. Artificial oxygen carriers: scientific and biotechnological points of view // Artif. Organs. – 2009. – Vol. 33. – ¹ 2. – P. 92-96. 83. Simoni J. Endothelial cell response to hemoglobin based oxygen carriers. Is the attenuation of pathological reactions possible? // In: Artificial Oxygen Carrier. Its Front Line. Kobayashi K, Tsuchida E, Horinouchi H, eds. / Tokyo: Springer-Verlag, 2005. – R. 25-75. 84. Simoni J., Simoni G., Moeller J.F. Intrinsic toxicity of hemoglobin: how to counteract it // Artif. Organs. – 2009. – Vol. 33. – ¹ 2. – P. 100-109. 85. Simoni J., Villanueva-Meyer J., Simoni G. et al. Control of oxidative reactions of hemoglobin in the design of blood substitutes: role of the ascorbate-glutathione antioxidant system // Artif. Organs. – 2009. – Vol. 33. – ¹ 2. – P. 115-126. 86. Sloan E.P., Koenigsberg M., Gens D. et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial // JAMA. – 1999. – Vol. 282. – ¹ 19. – R. 1857-1864. 87. Sou K., Klipper R., Goins B., et al. Circulation kinetics and organ distribution of Hb vesicles developed as a red blood cell substitute // J. Pharmacol. Exp. Ther. - 2005. - Vol. 312. - R.702-709. 88. Spahn D.R., Kocian R. Artificial O2 carriers: status in 2005 // Curr. Pharm. Des. – 2005. – Vol.11. – ¹ 31. – P. 4099-4114. 89. Sprung J., Kindscher J.D., Wahr J.A. et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized single-blind study // Anesth. Analg. – 2002. – Vol. 94. – ¹ 4. – R. 799-808. 90. Stowell C.P., Levin J., Spiess B.D., Winslow R.M. Progress in the development of RBC substitutes // Transfusion. – 2001. – Vol. 41. – ¹ 2 – R. 287-299. 91. Strauss R.G. Blood banking issues pertaining to neonatal red blood cell transfusions // Transfus. Sci. – 1999. – Vol.21. – ¹ 1. – P. 7-19. 92. Tsai A.G., Vandegriff K.D., Intaglietta M., Winslow R.M. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics // Am. J. Physiol. – 2003. – Vol. 285. – ¹ 4. – P. 1411-1419. 93. Vamvakas E.C., Taswell H.F. Epidemiology of blood transfusion // Transfusion. – 1994. – Vol.34. – ¹ 6. – P. 464-470. 94. Vandegriff K., Winslow R.M. Hemospan: design principles for a new class of oxygen therapeutic // Artif. Organs. – 2009. – Vol. 33. – ¹ 2. – P. 133-138. 95. Vandegriff K.D., Malavalli A., Wooldridge J. et al. MP4, a new nonvasoactive PEG-Hb conjugate // Transfusion. – 2003. – Vol. 43. – ¹4. – R. 509-516. 96. von Dobschuetz E., Hutter J., Hoffmann T., Messmer K. Recombinant human hemoglobin with reduced nitric oxide-scavenging capacity restores effectively pancreatic microcirculatory disorders in hemorrhagic shock // Anesthesiology. – 2004. – Vol. 100. – ¹ 6. – R. 1484-1490. 97. Winslow R. Current status of blood substitute research: towards a new paradigm // J. Intern. Med. – 2003. – Vol. 253. – ¹5. – P. 508–517. 98. Winslow R.M., Chapman K.W., Vandegriff K.D., Young M. Hemospan® (MP4), A human hemoglobin modified with maleimide-polyethylene glycol // In: Blood Substitutes. Ed. by R. Winslow / San Diego: Academic Press, 2006. – P. 470-482. 99. Winslow R.M., Lohman J., Malavalli A., Vandegriff K.D. Comparison of PEGmodified albumin and hemoglobin in extreme hemodilution in the rat // J. Appl. Physiol. – 2004. – Vol. 97. – ¹ 4. – P. 1527–1534. 100. Wong N., Chang T.M. Polyhemoglobin-fibrinogen: a novel oxygen carrier with platelet-like properties in a hemodiluted setting// Art. Cells Blood Substit. Immobil. Biotechnol. – 2007. – Vol. 35. – ¹ 5. – P. 481-489. 101. Yazer M.H., Triulzi D.J. Receipt of older RBCs does not predispose D-negative recipients to anti-D alloimmunization // Am. J. Clin. Pathol. – 2010. – Vol. 134. – ¹ 3. – R. 443- 447. 102. Young M.A., Lohman J., Malavalli A. et al. Hemospan improves outcome in a model of peri-operative hemodilution and blood loss in the rat: comparison with hydroxyethyl starch // J. Cardiothorac. Vasc. Anesth. – 2009. – Vol. 23. – ¹ 3. – R. 339-347. 103. Young M.A., Riddez L., Kjellström B.T. et al. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine // Crit. Care Med. – 2005. – Vol. 33. – ¹ 8. – P. 1794-1804. 104. Zhu X., Chu W., Wang F. et al. Variations in dominant antigen determinants of glutaraldehyde polymerized human, bovine and porcine hemoglobin // Art. Cells Blood Substit. Immobil. Biotechnol. – 2007. – Vol. 35. – ¹ 5. – P. 518-532. |
|||||||||
Articles
| Ðàçìåùåíèå ðåêëàìû | |
| |
 |